Video Recordings: ENRICH Clinical Trial
As ENRICH is the FIRST adaptive clinical trial designed with enrichment based on hemorrhage location, there are several questions surrounding this unique structure and how proper interpretation of results is essential for understanding the level of impact the data may provide. Are you curious to know:
- Why is trial design so important?
- How is ENRICH different from other ICH trials?
- Without p-values, how should data be interpreted?
Watch expert in novel Bayesian adaptive design and analysis, Dr. Ben Saville, PhD as he discusses key aspects of the ENRICH randomized adaptive clinical trial including population enrichment, flexible sample size, and why primary results will be presented without p-values.
Program Agenda
Novel Adaptive Clinical Trials
Landmark trials influencing patient care through adaptive design
What Makes ENRICH Different
- Novel Bayesian adaptive design
- Flexible sample size
- Population enrichment
- Innovative primary endpoint measure
Interim Adaptations
Advantages of population enrichment by hemorrhage location
Bayesian Probabilities Instead of p-values
Understanding the results of ENRICH
Q&A